subscribeSubscribe
Daiichi Sankyo`s Biologic Enhertu (fam-trastuzumab deruxtecan-nxki) Receives Approval in the U.S.

Daiichi Sankyo`s Biologic Enhertu (fam-trastuzumab deruxtecan-nxki) Receives Approval in the U.S.
FDA
15 Feb 2024
Share Share
AstraZeneca, Daiichi aim for first pan-tumor ADC approval

AstraZeneca, Daiichi aim for first pan-tumor ADC approval
Ben Fidler BIOPHARMADIVE
30 Jan 2024
Share Share
ENHERTU granted Priority Review for patients with HER2-positive solid tumors

ENHERTU granted Priority Review for patients with HER2-positive solid tumors
BUSINESSWIRE
29 Jan 2024
Share Share
Enhertu granted Priority Review in the US for patients with solid tumours

Enhertu granted Priority Review in the US for patients with solid tumours
PRESS RELEASE
29 Jan 2024
Share Share
Seagen patent invalidated in long-running Daiichi Sankyo spat

Seagen patent invalidated in long-running Daiichi Sankyo spat
FIERCE PHARMA
18 Jan 2024
Share Share
After Enhertu success, Daiichi and AstraZeneca branch off

After Enhertu success, Daiichi and AstraZeneca branch off
Annalee Armstrong FIERCE BIOTECH
25 Oct 2023
Share Share
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for NSCLC

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for NSCLC
BUSINESSWIRE
23 Oct 2023
Share Share
ENHERTU Demonstrated Survival Across Multiple HER2 Expressing Solid Tumors

ENHERTU Demonstrated Survival Across Multiple HER2 Expressing Solid Tumors
BUSINESSWIRE
23 Oct 2023
Share Share
AstraZeneca-Daiichi get some clarity on Enhertu follow up med

AstraZeneca-Daiichi get some clarity on Enhertu follow up med
Annalee Armstrong FIERCE BIOTECH
23 Oct 2023
Share Share
NICE poised to reject Enhertu in HER2-low breast cancer

NICE poised to reject Enhertu in HER2-low breast cancer
Angus Liu FIERCE PHARMA
28 Sep 2023
Share Share